2. Search Result
Search Result
Results for "

anti-androgens activity

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-135732
    SK33

    		Androgen Receptor Cancer
    SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity .
    SK33
  • HY-N9917
    Galloylalbiflorin

    6′-O-Galloylalbiflorin

    		 Androgen Receptor Endocrinology Cancer
    Galloylalbiflorin (6′-O-Galloylalbiflorin) is an androgen receptor (AR) antagonist (IC50=53.3 μM) and can be found in the roots of Paeonia lactiflora. Galloylalbiflorin shows anti-androgens activity .
    Galloylalbiflorin
  • HY-152512
    RLA-4842

    		Androgen Receptor Cancer
    RLA-4842 is an iron activator containing anti-androgen. RLA-4842 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line .
    RLA-4842
  • HY-152520
    RLA-5331

    		Androgen Receptor Cancer
    RLA-5331 is an iron activator containing anti-androgen. RLA-5331 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line .
    RLA-5331
  • HY-137444
    Ludaterone

    		Others Endocrinology
    Ludaterone is an antiandrogen agent, with potent antiandrogenic activity .
    Ludaterone
  • HY-148375
    Abiraterone sulfate

    		Drug Metabolite Others
    Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
    Abiraterone sulfate
  • HY-148376
    Abiraterone N-oxide

    		Drug Metabolite Cancer
    Abiraterone N-oxide is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
    Abiraterone N-oxide
  • HY-75054
    Abiraterone acetate
    10+ Cited Publications

    CB7630

    		 Cytochrome P450 Cancer
    Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    Abiraterone acetate
  • HY-137193
    5,6-Dihydroabiraterone

    		Drug Metabolite Cancer
    5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .
    5,6-Dihydroabiraterone
  • HY-75054S
    Abiraterone acetate-d4

    CB7630-d4

    		 Isotope-Labeled Compounds Cytochrome P450 Cancer
    Abiraterone acetate-d4 is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    Abiraterone acetate-d4
  • HY-75054R
    Abiraterone acetate (Standard)
    10+ Cited Publications

    CB7630 (Standard)

    		 Cytochrome P450 Cancer
    Abiraterone acetate (Standard) is the analytical standard of Abiraterone acetate. This product is intended for research and analytical applications. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    Abiraterone acetate (Standard)
  • HY-70013
    Abiraterone
    Maximum Cited Publications
    17 Publications Verification

    CB-7598

    		 Cytochrome P450 Cancer
    Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    Abiraterone
  • HY-70013S
    Abiraterone-d4

    CB-7598-d4

    		 Cytochrome P450 Cancer
    Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    Abiraterone-d4
  • HY-139970
    VPC-13789

    		Androgen Receptor Endocrinology Cancer
    VPC-13789 is a potent, selective, and orally bioavailable antiandrogen. VPC-13789 can be used for the research of castration-resistant prostate cancer (CRPC) therapeutics. VPC-13789 inhibits androgen receptor (AR) transcriptional activity in LNCaP cells (IC50=0.19 μM) .
    VPC-13789

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: